By Marcus Bennett

US restaurant operators face a compounding demand problem. Visits from value-seeking consumers softened through 2024 and into 2025. A new industry review now names a second structural concern. The spread of appetite-suppressing weight-loss drugs is reinforcing the existing weakness in US restaurant traffic. BusinessWorld Online framed the dynamic this week as additive rather than dominant — a sober characterization operators should weight carefully against their own comp data.

GLP-1 agonists — Ozempic, Wegovy, Mounjaro and Zepbound among them — suppress hunger signals, slow gastric emptying and reduce cravings. Clinical users report smaller meals, fewer snacks and lower alcohol intake. That behavior cuts into check averages and visit counts. A guest who orders an appetizer instead of an entrée removes dollars of contribution from each ticket. The math compounds across a quarter, especially at full-service concepts where beverage mix and dessert attachment matter as much as the entrée itself.

What changes for menu engineering?

The traditional US restaurant model sells abundance. Larger plates, shareable appetizers, value bundles and supersized drinks built the post-2000 traffic base. GLP-1 users want the opposite. They want sufficiency, not surplus. Operators serving meaningful numbers of therapy patients will need to rethink plate cost as a share of check. The ratio of appetizers to entrees will shift. Combo meals built around carbonated drinks will lose relevance as calorie-conscious diners increasingly order water or skip dessert.

How big is the actual exposure?

That remains the open question. GLP-1 prescriptions have grown rapidly since 2022. The share of regular restaurant patrons actively on therapy is not publicly broken out. The BusinessWorld review calls the drug effect marginal pressure layered on weak underlying traffic, not the primary cause of the slowdown. The sober note is that biology does not respond to discounting. A consumer pulled away by price can be coaxed back with value offers. A consumer pulled away by satiety hormones cannot. That distinction is the central operational risk for the next planning cycle.

What is the forward path?

Three signals will clarify exposure in the quarters ahead. First, prescription volumes at the major pharmacy benefit managers and retail pharmacy chains. Second, menu adjustments publicly announced by the top twenty US chains, with attention to smaller portions and protein-forward items. Third, same-store-sales disclosures that separate traffic from ticket. Until those numbers land, operators are estimating in the dark.

The labor math compounds the concern. A 200-seat dining room turning the same covers on smaller tickets sees food cost held steady as a percentage of revenue, while labor cost rises. A shift from a $14 average check to $11, holding food cost near 28 percent, lifts labor from roughly 28 percent of revenue toward 36 percent. Operators who do not adjust portion sizes and table turns will see four-wall margin compression that staffing cuts cannot offset. Menu price actions will follow. Expect value-ladder rebuilding at scale-limited concepts and entrée-price relief at full-service operators. The chains that publish smaller-portion, lower-priced options first will likely take share from those resisting the structural reset.

The bar program also warrants attention, since alcohol consumption drops sharply among GLP-1 users, pressuring beverage revenue at full-service concepts in particular.

The industry's challenge is structural. It is not cyclical. Restaurants that built expansion plans on rising check averages will need to revise those assumptions. Smaller formats, leaner menus and tighter labor models will replace the supersizing economics of the last two decades — quietly, and faster than the headline traffic data alone would suggest.